CoChat
Sign Up
Cited by 106Gastrointestinal motility and disordersProbiotics and Fermented FoodsGut microbiota and health

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Irritable bowel syndrome symptom severity improves equally with probiotic and placebo

Open access
Lyra, Anna, Hillilä, Markku, Huttunen, Teppo, Männikkö, Sofia, Taalikka, Mikko, Tennilä, Julia, Tarpila, Anneli, Lahtinen, Sampo, Ouwehand, Arthur C, Veijola, Lea·2016·World Journal of Gastroenterology
DOI 10.3748/wjg.v22.i48.10631PMC PMC5192275
Open this paper in CoChat — free account

Abstract

AIM: NCFM on irritable bowel syndrome (IBS) symptoms and quality of life (QoL). METHODS: colony-forming units of NCFM or placebo daily for 12 wk. IBS Symptom Severity Score (IBS-SSS), which constituted the primary outcome, and secondary outcomes, including individual IBS symptoms, IBS-related QoL questionnaire, anxiety and depression, defecation frequency, and stool consistency, were assessed at baseline at the end of the 8-wk run-in period, after 4 and 12 wk of intervention, and after a 4-wk washout. RESULTS: combined active doses = 0.0460). CONCLUSION: NCFM alleviates moderate to severe abdominal pain, consistent with earlier observations of this strain mitigating visceral pain through increased analgesic receptor expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v22.i48.10631

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study outline. Volunteers were selected for screening visits by a prescreen for compliance over the phone. Eligible volunteers entered an 8-wk run-in period without any investigational product (IP) consumption and were thereafter randomized to receive low- or high-dose active IP or a placebo IP for 12 wk. The intervention period was followed by a 4-wk washout period without any IP consumption. Preceding each time point (weeks 0, 4, 12, and 16), volunteers recorded their stool consistency during each defecation event for 7 d. At each time point, questionnaires [Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS); IBS-related Quality of Life (IBS-QoL); Hospital Anxiety and Depression Score (HADS)] were filled out. All volunteers were contacted by phone prior to each sampling time point to inquire about adverse events (AEs) and to remind of the sampling procedures.
Figure 1 Study outline. Volunteers were selected for screening visits by a prescreen for compliance over the phone. Eligible volunteers entered an 8-wk run-in period without any investigational product (IP) consumption and were thereafter randomized to receive low- or high-dose active IP or a placebo IP for 12 wk. The intervention period was followed by a 4-wk washout period without any IP consumption. Preceding each time point (weeks 0, 4, 12, and 16), volunteers recorded their stool consistency during each defecation event for 7 d. At each time point, questionnaires [Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS); IBS-related Quality of Life (IBS-QoL); Hospital Anxiety and Depression Score (HADS)] were filled out. All volunteers were contacted by phone prior to each sampling time point to inquire about adverse events (AEs) and to remind of the sampling procedures.CC BY-NC · PubMed Central
Figure 2 Disposition of volunteers. During the 8-wk run-in period prior to randomization, 17% of eligible volunteers dropped out. After randomization, most volunteers (87%) completed the trial. Withdrawals were evenly distributed between treatment groups. Low- and high-dose treatment groups received 109 or 1010 CFU Lactobacillus acidophilus NCFM daily.
Figure 2 Disposition of volunteers. During the 8-wk run-in period prior to randomization, 17% of eligible volunteers dropped out. After randomization, most volunteers (87%) completed the trial. Withdrawals were evenly distributed between treatment groups. Low- and high-dose treatment groups received 109 or 1010 CFU Lactobacillus acidophilus NCFM daily.CC BY-NC · PubMed Central
Figure 3 Irritable bowel syndrome symptom severity score over time. IBS-SSS is a 5-item composite score inquiring about the severity of abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life on a 10-cm VAS scale and the number of days with abdominal pain over the past 10 d[18]. All items are scored from 0 to 100, allowing for IBS-SSSs to range from 0 to 500. Francis and colleagues have validated non-IBS controls and volunteers suffering from mild, moderate, and severe IBS symptoms to range between 0-75, 75-175, 175-300, and 300-500, respectively[18]. The composite symptom score declined similarly in all treatment groups during the intervention, showing no treatment effect for the active groups (low-dose and high-dose) receiving Lactobacillus acidophilus NCFM. The severity scores are given as mean ± SD. Differences from baseline to week 12 were not significant between treatment groups. All within-group comparisons to baseline (week 4, week 12, and washout) were significant (P < 0.001). IBS-SSS: Irritable bowel syndrome symptom severity score; IBS: Irritable bowel syndrome.
Figure 3 Irritable bowel syndrome symptom severity score over time. IBS-SSS is a 5-item composite score inquiring about the severity of abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life on a 10-cm VAS scale and the number of days with abdominal pain over the past 10 d[18]. All items are scored from 0 to 100, allowing for IBS-SSSs to range from 0 to 500. Francis and colleagues have validated non-IBS controls and volunteers suffering from mild, moderate, and severe IBS symptoms to range between 0-75, 75-175, 175-300, and 300-500, respectively[18]. The composite symptom score declined similarly in all treatment groups during the intervention, showing no treatment effect for the active groups (low-dose and high-dose) receiving Lactobacillus acidophilus NCFM. The severity scores are given as mean ± SD. Differences from baseline to week 12 were not significant between treatment groups. All within-group comparisons to baseline (week 4, week 12, and washout) were significant (P < 0.001). IBS-SSS: Irritable bowel syndrome symptom severity score; IBS: Irritable bowel syndrome.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., Tarpila, A., Lahtinen, S., Ouwehand, A. C., & Veijola, L.
Affiliations
DuPont (Finland) (FI)
ORCID
Venue
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc.
Published
2016
Volume
22
Issue
48
Pages
10631
ISSN
1007-9327 (ISSN-L)
DOI
10.3748/wjg.v22.i48.10631
PMC
PMC5192275
OpenAlex
W2560913755
Cited by
106
References
35
Citations by year
2026: 5 · 2025: 8 · 2024: 11 · 2023: 16 · 2022: 15 · 2021: 17 · 2020: 14 · 2019: 8 · 2018: 10 · 2017: 1 · 2016: 1
FWCI
7.30
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
irritable bowel syndrome, probiotics, placebo, symptom severity, quality of life, abdominal pain, anxiety, depression, stool frequency, stool consistency, visceral pain
MeSH terms
Adult, Colon, Dose-Response Relationship, Drug, Female, Humans, Intestinal Mucosa, Lactobacillus acidophilus, Male, Middle Aged, Pain Measurement, Surveys and Questionnaires, Receptors, Opioid, Severity of Illness Index, Abdominal Pain, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Visceral Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review